Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
about
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibitionEpidermal growth factor receptor and notch signaling in non-small-cell lung cancerActivation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis.Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancerOptimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.Pazopanib diminishes non-small cell lung cancer (NSCLC) growth and metastases in vivoUpdate on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?Targeted therapies for lung cancer: clinical experience and novel agentsConcise drug review: pazopanib and axitinib.Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients.Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Targeting angiogenesis in lung cancer - Pitfalls in drug development.Best practice in the treatment of advanced squamous cell lung cancer.Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors.Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cellsTargeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model.Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT.A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.
P2860
Q24616631-87904102-EE4C-456F-B685-300079863FC2Q28080187-90D5366E-AA24-4EA6-AEB2-F9115ED82A65Q33789403-33C84BA5-F0B7-41EE-BDD6-4604CEF54B31Q34092023-0A662E85-49A7-4E18-B704-339D405FE39BQ34484368-622DF155-53F6-4E47-B3E7-C4A0BA967268Q34754045-C7201827-4F8C-4B2F-A7CA-2CD4713F22A5Q34836398-ED90DA1D-542A-4874-9380-FF52F516BA98Q35307851-4395410D-A23C-4A6D-A5D9-BC135BA667FEQ35663577-45A34CF2-9EE1-40DD-A1E8-A6DE012B0CE8Q35667802-48AF309B-E1C0-4348-A5BA-7AAF4CF556EBQ36054970-CF383EC3-5EA0-4968-95BB-7304AD1079C5Q36182836-28261A44-6576-4312-B105-4290DA6E6FF7Q36524729-81CE496B-AC4C-4728-987F-11BC64FDF017Q36996220-259FBA9F-FBB7-4A2F-A5FB-874AA3E7851BQ38389997-01ED7476-3511-4084-B82B-EAD1E0AF71D2Q38435967-BAC130B2-BA99-46CF-8143-1209878ABE22Q38754455-697D6081-F400-4A62-8C83-C52B67A95169Q38825333-8E26C613-F35B-4BE8-A00C-6636FAFDF3ACQ38964908-67B19CB3-F82E-4EC9-B8E0-0BB847AC639DQ39397672-A00DB99C-9E70-4F06-A29C-B98D2F91E998Q42730901-7F697509-55DF-457F-8158-F7186231BAF5Q47769528-313AC84B-E124-4810-92EE-D81D72C6A802Q52992671-9104B5F2-5B41-4006-B483-9722C3347C9DQ54320201-59EE99E9-8B5F-40D8-8927-C80DFBCDA936Q54978333-6745E40A-BD88-4B54-A1BD-0353DA36B62D
P2860
Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Targeting angiogenesis with mu ...... of non-small cell lung cancer.
@ast
Targeting angiogenesis with mu ...... of non-small cell lung cancer.
@en
type
label
Targeting angiogenesis with mu ...... of non-small cell lung cancer.
@ast
Targeting angiogenesis with mu ...... of non-small cell lung cancer.
@en
prefLabel
Targeting angiogenesis with mu ...... of non-small cell lung cancer.
@ast
Targeting angiogenesis with mu ...... of non-small cell lung cancer.
@en
P2860
P921
P1433
P1476
Targeting angiogenesis with mu ...... of non-small cell lung cancer.
@en
P2093
Giorgio Scagliotti
Ramaswamy Govindan
P2860
P304
P356
10.1634/THEONCOLOGIST.2009-0225
P577
2010-04-28T00:00:00Z